ContraVir Pharmaceuticals Inc.

ContraVir Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. The company's lead candidate is FV-100, a potent oral antiviral that is being developed for the treatment of herpes zoster, commonly known as shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent than current FDA-approved drugs.